Forest Laboratories, Inc. (FRX), Merz Pharma GmbH & Co. KGaA Settle Patent Dispute Over Namenda
7/23/2010 7:16:14 AM
More...
|
Neurobiological Technologies, Inc. (NTII) Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
2/3/2009 8:26:16 AM
More...
|
Forest Laboratories, Inc. (FRX) and Merz Pharma GmbH & Co. KGaA File Additional Lawsuit Against Several Companies for Patent Infringement
1/25/2008 11:20:45 AM
More...
|
Forest Laboratories, Inc. (FRX) and Merz GmbH & Co. KGaA File Lawsuits Against Several Companies for Patent Infringement
1/11/2008 7:54:30 AM
More...
|
Bernhard Scheuble Appointed As CEO Of The MERZ Group
9/27/2006 1:51:01 PM
More...
|
Neurobiological Technologies, Inc. (NTII) Receives $1.1 Million Royalty Payment Related To Memantine
10/19/2005 5:10:41 PM
More...
|
Forest Laboratories, Inc. (FRX) Announces That Neramexane Did Not Demonstrate Statistical Significance In Recently Completed Phase III Trial In Patients With Moderate To Severe Alzheimer's Disease
10/19/2005 5:10:29 PM
More...
|
Merz GmbH & Co. KGaA Release: Memantine Captures US Market
10/19/2005 5:10:11 PM
More...
|
Neurobiological Technologies, Inc. (NTII) Receives $2.25 Million Payment Related To Alzheimer's Drug
10/19/2005 5:09:55 PM
More...
|